APO-Mometasone nasal spray recalled due to infection risk
Drug company Apotex is recalling two lots of its prescription nasal spray because of possible bacterial contamination. (Source: CBC | Health)
Source: CBC | Health - February 20, 2024 Category: Consumer Health News Tags: News/Health Source Type: news

Intranasal Saline May Suffice for Some Kids' Sleep-Disordered Breathing
(MedPage Today) -- Intranasal mometasone furoate was no better than saline for resolving symptoms of sleep-disordered breathing (SDB) in children, but either treatment may reduce the need for specialty care or surgery, the randomized MIST trial... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - January 18, 2023 Category: Psychiatry Source Type: news

New Nasal Spray for Seasonal Allergic Rhinitis New Nasal Spray for Seasonal Allergic Rhinitis
Patients with both nasal and ocular symptoms of SAR have a new treatment option that combines olopatadine hydrochloride and mometasone furoate in the form of a nasal spray.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 7, 2022 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news

Glenmark's partner Hikma launches specialty drug Ryaltris in US
Ryaltris is the only fixed-dose combination of olopatadine hydrochloride and mometasone furoate approved by the USFDA for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older. Glenmark developed the drug, while Hikma will commercialise it in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 30, 2022 Category: Pharmaceuticals Source Type: news

FDA Approves Nasonex 24HR Allergy (mometasone furoate) Nasal Spray for OTC Use
DUBLIN, March 17, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 17, 2022 Category: Drugs & Pharmacology Source Type: news

FDA Approves Ryaltris (mometasone and olopatadine) Nasal Spray for Seasonal Allergic Rhinitis
Mumbai (Maharashtra) [India], January 14, 2022 (ANI/PRNewswire) -- Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company announced that its fully owned subsidiary Glenmark Specialty S.A. (Switzerland), received... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 14, 2022 Category: Drugs & Pharmacology Source Type: news

Class 4 Medicines Defect Information: Mometasone Furoate 50 Microgram / Dose Nasal Spray, Suspension
There is an error relating to the wording on the outer carton label for Mometasone Furoate 50 Microgram / Dose Nasal Spray, supplied by PilsCo Ltd. Further information and advice for healthcare profe (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 1, 2021 Category: Drugs & Pharmacology Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment ...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment ...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news

Sinuva (Mometasone Furoate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 8, 2020 Category: Drugs & Pharmacology Source Type: news

Dulera (mometasone furoate/formoterol fumarate)
Title: Dulera (mometasone furoate/formoterol fumarate)Category: MedicationsCreated: 10/21/2015 12:00:00 AMLast Editorial Review: 8/20/2019 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - August 20, 2019 Category: Respiratory Medicine Source Type: news

New Approval Helps Implanting Propel Mini a Little Bit Easier
Intersect ENT has received a nod from FDA for a new delivery system to use for its sinus implant. The Menlo Park, CA-based company said the approval was for its Straight Delivery System for use to place the Propel Mini steroid releasing sinus implant in the ethmoid sinus. PROPEL Mini helps maintain the sinus opening while delivering mometasone furoate directly where it is needed, improving outcomes of frontal (behind the forehead) and ethmoid (behind the bridge of the nose) sinus surgery. The new SDS is designed to help physicians achieve precise and easy delivery of the PROPEL Mini implant to the ethmoid sinus. The compan...
Source: MDDI - July 29, 2019 Category: Medical Devices Authors: MDDI Staff Tags: Implants Source Type: news

Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate, glycopyrronium bromide and mometasone furoate, delivered with the dose-confirming Breezhaler® inhalation device, was presented at the 2019 annual international congress of the American Thoracic Society (ATS). (Source: World Pharma News)
Source: World Pharma News - May 22, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris(TM), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years
The study of Ryaltris (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg] nasal spray) in pediatric patients aged 6 to under 12 years of age met its primary endpoint, and results were consistent with extensive clinical trial experience wit... Biopharmaceuticals Glenmark Pharmaceuticals, Ryaltris, olopatadine, seasonal allergic rhinitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 8, 2019 Category: Pharmaceuticals Source Type: news